Watch Ron Lanton give Specialty Pharmacy Times his insight on the Prescription Drug Price Relief Act.
Read More
Oftentimes policy changes that sweep across the nation originate in policy “hot spots” like Massachusetts, California, New York, etc. This time its consumer privacy. As we rely more and more on the internet of things, artificial intelligence and fitness applications, we are unfortunately becoming more exposed to potential data breaches. If you operate in California, the California Consumer Privacy Act (CCPA) will be a defining factor in how you manage risks around consumer data.
Read More
Cannabidiol (CBD) has certainly drawn significant attention over the past few months. Marked by the recent passage of the Farm Bill and the FDA’s hearing on CBD at the end of May, the curiosity about and demand for the products have never been stronger. Unfortunately, misinformation on the effects of CBD remains rampant, including details on whether combining CBD with food affects the body’s absorption and conflicting reports on the various differences in state regulation.
Read More
For years we have witnessed the fierce debate over whether the North American Free Trade Agreement (NAFTA) is serving the best interests of the United States. In following up on a 2016 campaign promise to renegotiate NAFTA, the new NAFTA, called the United States–Mexico–Canada Agreement (USMCA), is currently being debated by Congress, and there are concerns as to whether the agreement will be ratified.
Read More
Just prior to an election season, it is not surprising to see a few bills emerge as potential silver bullets to solve pressing policy issues. The latest issue that has consumed the public for several years is how to lower drug prices. While policymakers have raised a series of threats to the industry, such as having Medicare negotiate drug prices, getting rid of drug rebates, and the specter of importation, none of these threats have yet to materialize into any meaningful legislation. What has remained consistent is the intrigue of biosimilars and whether finding ways to increase their utilization in the market could provide the elusive key to lowering drug costs. Two Congressional bills have recently emerged illustrating this desire.
Read More